INOVIQ Ltd
ASX:IIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fujian Dongbai Group Co Ltd
SSE:600693
|
CN |
|
S
|
Shandong Bohui Paper Industry Co Ltd
SSE:600966
|
CN |
|
Shanghai Join Buy Co Ltd
SSE:600838
|
CN |
INOVIQ Ltd
R&D
INOVIQ Ltd
R&D Peer Comparison
INOVIQ Ltd
Glance View
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is focused on developing and commercializing a portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Company’s products include hTERT ICC test, which is an immunocytochemistry (ICC) assay that detects hTERT and is used as an adjunct to urine cytology, and EXO-NET RUO, which is a pan-exosome capture tool for isolation of exosomes from body fluids including plasma, urine, and saliva. The company is also developing solutions using SubB2M, NETs, BARD1 and hTERT technologies to improve patient health outcomes.
See Also
What is INOVIQ Ltd's R&D?
R&D
-3.3m
AUD
Based on the financial report for Jun 30, 2025, INOVIQ Ltd's R&D amounts to -3.3m AUD.
What is INOVIQ Ltd's R&D growth rate?
R&D CAGR 5Y
-45%
Over the last year, the R&D growth was -21%. The average annual R&D growth rates for INOVIQ Ltd have been -2% over the past three years , -45% over the past five years .
